Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 291-300 of 3338 for cancer

Edit search filters
  1. Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

    Rochester, MN

  2. A Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Platinum-Refractory Metastatic Bladder Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

    Rochester, MN

  4. Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer

    Rochester, MN

  5. Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

    Rochester, MN

  6. Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study to Evaluate Adjuvant Ado-Trastuzumab Emtansine (T-DM1) in HER2 Positive Breast Cancer

    Rochester, MN

  8. A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer

    Rochester, MN

  9. Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer